MX2017013687A - Polipeptidos dirigidos a la fusion de vih. - Google Patents

Polipeptidos dirigidos a la fusion de vih.

Info

Publication number
MX2017013687A
MX2017013687A MX2017013687A MX2017013687A MX2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A MX 2017013687 A MX2017013687 A MX 2017013687A
Authority
MX
Mexico
Prior art keywords
hiv fusion
polypeptides
targeting hiv
polypeptides targeting
fibronectin
Prior art date
Application number
MX2017013687A
Other languages
English (en)
Inventor
Davis Jonathan
R Krystal Mark
L Wensel David
Original Assignee
Viiv Healthcare Uk No 5 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viiv Healthcare Uk No 5 Ltd filed Critical Viiv Healthcare Uk No 5 Ltd
Publication of MX2017013687A publication Critical patent/MX2017013687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Immunology (AREA)

Abstract

La invención se refiere a polipóptidos que comprenden una porción de fijación a CD4, una porción de fijación a gp41, una porción inhibidora peptí­dica de la fusión de VIH y combinaciones de estas. Más especí­ficamente, la presente invención se refiere a polipóptidos que comprenden una proteí­na del dominio de andamiaje a base de fibronectina que se fija a CD4, una proteí­na del dominio de andamiaje a base de fibronectina que se fija al dominio N17 de gp41 y un inhibidor peptí­dico de la fusión de VIH, o combinaciones de estos. La invención también se refiere al uso de las proteí­nas innovadoras en aplicaciones terapéuticas para tratar el VIH.
MX2017013687A 2015-04-24 2016-04-14 Polipeptidos dirigidos a la fusion de vih. MX2017013687A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US201562257474P 2015-11-19 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Publications (1)

Publication Number Publication Date
MX2017013687A true MX2017013687A (es) 2018-07-06

Family

ID=55809237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013687A MX2017013687A (es) 2015-04-24 2016-04-14 Polipeptidos dirigidos a la fusion de vih.

Country Status (25)

Country Link
US (2) US10407490B2 (es)
EP (2) EP3985020A1 (es)
JP (3) JP6894846B2 (es)
KR (1) KR20170138558A (es)
CN (1) CN107922474A (es)
AU (2) AU2016252008B2 (es)
BR (1) BR112017022790A2 (es)
CA (1) CA2983276A1 (es)
CL (1) CL2017002687A1 (es)
CO (1) CO2017011583A2 (es)
CR (1) CR20170482A (es)
DO (1) DOP2017000246A (es)
EA (1) EA035332B1 (es)
ES (1) ES2884267T3 (es)
HK (1) HK1243432A1 (es)
IL (1) IL255122A0 (es)
MA (2) MA41943A (es)
MX (1) MX2017013687A (es)
PE (1) PE20180162A1 (es)
PH (1) PH12017501914A1 (es)
PT (1) PT3286212T (es)
SG (1) SG11201708441RA (es)
TW (1) TW201643185A (es)
UY (1) UY36650A (es)
WO (1) WO2016171980A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
WO2019123262A1 (en) 2017-12-18 2019-06-27 VIIV Healthcare UK (No.5) Limited Antigen binding polypeptides
CN114605505B (zh) * 2018-08-09 2023-01-31 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
CA3230492A1 (en) * 2021-08-30 2023-03-09 Kanglin Biotechnology (Hangzhou) Co., Ltd. Gene sequence construct for gene therapy for hiv infection

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP3095175B2 (ja) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Ｂ細胞リンパ腫の治療のためのヒトｂリンパ球限定分化抗原に対するキメラ抗体と放射能標識抗体の療法利用
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
ES2564161T3 (es) 2000-07-11 2016-03-18 Research Corporation Technologies, Inc Polipéptidos de anticuerpos artificiales
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
MXPA05002851A (es) * 2002-09-27 2005-09-08 Tanox Inc Composiciones sinergicas para la prevencion y el tratamiento del sindrome de inmunodeficiencia adquirida.
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
SI1729795T1 (sl) 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
AR067584A1 (es) * 2007-07-20 2009-10-14 Hoffmann La Roche Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos
EP2234646A2 (en) 2007-12-27 2010-10-06 Novartis AG Improved fibronectin-based binding molecules and their use
PL2439212T3 (pl) 2008-05-02 2017-06-30 Novartis Ag Ulepszone cząsteczki wiążące na bazie fibronektyny oraz ich zastosowanie
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20130108653A1 (en) * 2009-12-22 2013-05-02 Shervin Bahrami Bivalent molecules for hiv entry inhibition
PE20130238A1 (es) 2010-04-13 2013-03-11 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina que se unen a la proproteina convertasa subtilisina kexina tipo 9 (pcsk9)
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
RU2012148816A (ru) * 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
US9260496B2 (en) 2010-12-22 2016-02-16 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
WO2012159164A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
EA035150B1 (ru) 2011-09-27 2020-05-06 Янссен Байотек, Инк. Способ получения белковых каркасов на основе фибронектинового домена типа iii с альтернативными поверхностями связывания
WO2014120891A2 (en) * 2013-02-01 2014-08-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
US20160152686A1 (en) * 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Also Published As

Publication number Publication date
CL2017002687A1 (es) 2018-04-20
EP3985020A1 (en) 2022-04-20
PE20180162A1 (es) 2018-01-18
EA035332B1 (ru) 2020-05-28
JP6894846B2 (ja) 2021-06-30
US10407490B2 (en) 2019-09-10
HK1243432A1 (zh) 2018-07-13
EP3286212B1 (en) 2021-06-02
UY36650A (es) 2016-11-30
AU2016252008B2 (en) 2019-06-13
JP2021035951A (ja) 2021-03-04
KR20170138558A (ko) 2017-12-15
TW201643185A (zh) 2016-12-16
MA41943A (fr) 2018-02-28
PH12017501914A1 (en) 2018-03-05
WO2016171980A1 (en) 2016-10-27
SG11201708441RA (en) 2017-11-29
IL255122A0 (en) 2017-12-31
EA201792269A1 (ru) 2018-04-30
US11155602B2 (en) 2021-10-26
AU2016252008A1 (en) 2017-11-09
AU2019226255A1 (en) 2019-09-26
CN107922474A (zh) 2018-04-17
CO2017011583A2 (es) 2018-04-19
ES2884267T3 (es) 2021-12-10
BR112017022790A2 (pt) 2018-07-17
US20190359688A1 (en) 2019-11-28
EP3286212A1 (en) 2018-02-28
JP2023055875A (ja) 2023-04-18
JP2018516247A (ja) 2018-06-21
DOP2017000246A (es) 2018-01-31
CA2983276A1 (en) 2016-10-27
US20180111980A1 (en) 2018-04-26
JP7465378B2 (ja) 2024-04-10
MA56222A (fr) 2022-04-20
PT3286212T (pt) 2021-08-24
CR20170482A (es) 2018-03-07

Similar Documents

Publication Publication Date Title
PH12017501914A1 (en) Polypeptides targeting hiv fusion
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
MX2022013841A (es) Inhibidores de la interaccion de menina-mll.
MX2023002982A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
CY1124756T1 (el) Εξουδετερωτικα αντισωματα του ιου ανθρωπινης ανοσοανεπαρκειας
GB2578802B (en) Programmable DNA binding proteins that increase efficiency and/or specificity of genome targeting in eukaryotic cells for use in therapy
PH12021500001A1 (en) Antibodies that target hiv gp120 and methods of use
WO2015109124A3 (en) Immunomodulatory agents
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2021003475A (es) Metodos de purificacion de proteinas.
MX2017014056A (es) Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos.
BR112016020377A2 (pt) proteínas fc multiméricas
CR20170020A (es) Variantes de proteínas de unión al factor h y métodos de uso de estas
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
CY1125014T1 (el) Υποκατεστημενα παραγωγα ξανθινης
MX2018000839A (es) Construccion dirigida a complejos de peptido de antigeno prostatico especifico (psa)/complejo mayor de histocompatibilidad (mhc) y usos de los mismos.
WO2018132696A3 (en) Stomach acid-stable and mucin-binding protein-polymer conjugates
WO2018057967A3 (en) Constructs targeting hiv peptide/mhc complexes and uses thereof
MX2016015560A (es) Farmaco antirretroviral dirigido a un retrovirus endogeno humano.
PH12018500645A1 (en) Hiv antibody compositions and methods of use
AR104390A1 (es) Polipéptidos dirigidos a la fusión de vih
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
EA201992151A1 (ru) Фармацевтические композиции для комбинированной терапии
WO2015134854A3 (en) Small molecule vif dimerization antagonists as anti-hiv agents and for use as hiv/aids therapeutics